SCHEMBL5148549

SCHEMBL5148549

CCOC(=O)CCc1cnn2c1NCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.40
CYP4A11 Q02928 2/20 0.40
TSHR P16473 1/20 0.38
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
LMNA P02545 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
MAPT P10636 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 2/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
KDM2B Q8NHM5 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18395054 0.77 LMNA (0.48) TSHRALDH1A1LMNAL3MBTL1MAPT
SCHEMBL5151750 0.71 CYP4F2 (0.40) CYP4F2CYP4A11TSHRALDH1A1GAA
SCHEMBL9020033 0.69 LMNA (0.44) TSHRALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL9869341 0.66 POLB (0.38) ALDH1A1L3MBTL1KDM4EPOLBCCNT1
SCHEMBL17869465 0.64 CHRNB2 (0.31) CCNT1CDK9
SCHEMBL23599088 0.64 CYP4F2 (0.53) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL30178437 0.64 CYP4F2 (0.53) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL6133131 0.64 CYP4F2 (0.51) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL27224521 0.64 CYP4F2 (0.56) CYP4F2CYP4A11ALDH1A1GAALMNA
SCHEMBL3542834 0.63 ALDH1A1 (0.41) CYP4F2CYP4A11ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179801-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-02-20 US disclosed
EP-1392704-B1 CEPHEM COMPOUNDS ASTELLAS PHARMA INC (JP) 2006-02-22 EP disclosed
US-20040248875-A1 Cephem compounds ASTELLAS PHARMA INC. (JP) 2004-12-09 US disclosed
EP-1392704-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-03 EP disclosed
WO-2002090364-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248875-A1 Cephem compounds CEP170, C1S, SLC7A1 CYP4F2 353/4885CYP4A11 790/4885TSHR 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.